CTXR - Company ID 0001506251
Citius Pharmaceuticals, Inc. (CTXR) reported net income of -$32.54M for fiscal year 2023, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2023 | -$32.54M | +3.3% |
| FY 2022 | -$33.64M | -45.9% |
| FY 2021 | -$23.05M | -31.4% |
| FY 2020 | -$17.55M | -12.8% |
| FY 2019 | -$15.56M | -24.1% |
| FY 2018 | -$12.54M | -20.7% |
| FY 2017 | -$10.38M | -25.2% |
| FY 2016 | -$8.30M | -185.8% |
| FY 2015 |
Between fiscal 2010 and fiscal 2023, Citius Pharmaceuticals, Inc.'s net income declined from -$15.50K to -$32.54M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$2.90M |
| -293.4% |
| FY 2014 | -$737.73K | +42.7% |
| FY 2013 | -$1.29M | -22.7% |
| FY 2012 | -$1.05M | -3884.0% |
| FY 2011 | -$26.34K | -69.9% |
| FY 2010 | -$15.50K | - |